anti-obesity drug to be approved by the FDA in over 10 years. This is following the approval of Belviq (Arena Pharmaceuticals (NASDAQ: ARNA )) and Qsymia (Vivus (NASDAQ: VVUS )) back in 2012. Following its approval, OREX stock has
By Spencer Osborne : Sales of the Arena Pharmaceuticals (NASDAQ: ARNA ) anti-obesity pill Belviq seem to be seeing some impacts of seasonality with ups and downs as the Fall weeks
Small cap Tetraphase Pharmaceuticals ( TTPH +14.6% ) jumps on a 3x surge in volume. Yesterday evening it announced the pricing of its public offering of 3.95M
files suit in the U.S. District Court of Delaware against Sanofi (NYSE: SNY ) ( OTCQB:SNYNF ) and Regeneron Pharmaceuticals (NASDAQ: REGN ) alleging infringement on three of its patents covering monoclonal antibodies to proprotein convertase
Oct 17 (Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis.
By Don Dion : Xenon Pharmaceuticals (Pending: XENE ) recently filed with the Securities and ..... Company Overview Located in British Columbia, Canada, Xenon Pharmaceuticals is a clinical stage biopharmaceutical company that is focused
Mesoblast partner Teva Pharmaceuticals has announced it will discontinue or divest 14 pipeline projects, primarily in oncology and women's health, following the results
2014, 08:00 AM ET Executives Severin Schwan - Chief Executive Officer Dan O'Day - Chief Operating Officer, Pharmaceuticals Roland Diggelmann - Chief Operating Officer, Diagnostics Alan Hippe - Chief Financial Officer and IT Officer Analysts
TORONTO (Reuters) - Billionaire investor William Ackman turned up the heat on Allergan Inc. on Thursday when he accused the Botox maker’s board of misleading investors to fend off a hostile takeover bid from Valeant Pharmaceuticals .
TORONTO, Oct 16 (Reuters) - Billionaire investor William Ackman turned up the heat on Allergan Inc. on Thursday when he accused the Botox maker's board of misleading investors to fend off a hostile takeover bid from Valeant Pharmaceuticals .